Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT) » Mucosamin – Zapobieganie i leczenie zapalenia błony śluzowej wywołanego radioterapią, chemioterapią oraz leczeniem skojarzonym.

PRODUKT OBJĘTY BADANIEM: MUCOSAMIN SPRAY

Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT)

Study:

Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT)

Design:

137 patients were divided in 4 groups:

Group A (37 patients): all received a complete session of professional oral health care (POHC) and Mucosamin spray on mucositis lesions 3-4 times a day after a meal.
Group B (32 patients): all received a complete session of professional oral health care (POHC) and Clorexidine 0.20%.
Group C (34 patients): received Mucosamin spray on mucositis lesions 3-4 times a day after a meal.
Group D (34 patients): received only Clorexidine 0.20% on oral mucositis lesions.

Measurements:

VAS scale.
Score for oral mucositis – WHO grade scale for oral mucositis: light mucositis WHO grade 1 and 2; severe mucositis WHO grade 3 and 4.

ORAL MUCOSITIS PREVALENCE

WHO GRADE OF OM

OMAS GRADE OF OM

ORAL MUCOSITIS GRAVITY

Wyniki kliniczne

Treated patients with Mucosamin Spray developed less severe mucositis.
Treated patients with Mucosamin Spray resolved the mucositis in less time.
Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.

Ruggiero T. et al.
Journal of Biological Regulators & Homeostatic Agents
Vol. 32, no. 3, 737-743
2018

Skontaktuj się z przedstawicielem aby otrzymać ofertę dla specjalistów